The Edge's boss Tong Kooi Ong bought 48 lots of Maybulk at 0.52.

Both ANCOM and NYLEX are not really making money. Fishy companies. I'd personally prefer not to enter. And btw ANCOM also owns Malay Mail.

Goldberg, that's ANCOM. One of the few major producers of ethanol via its subsidiary.

Continue ...

Can we fix the supply problem before the pandemic ends?
China seems to have its outbreak relatively under control, and it has now somewhat eased limits on exports of medical supplies. This is good news, but the steps so far will not meet the overall increased demand.

The pandemic will continue to wreak havoc with logistics, creating bottlenecks that have slowed the movement of supplies. Pandemic restrictions, in particular physical distancing, slow down almost every part of the process, especially production. And some of our suppliers tell us that they are starting to see shortages in the raw materials they need for production, such as the material typically used to make isolation gowns. So it’s likely that health care providers will continue to rely more on domestic suppliers.

There are some benefits to this turn to US supplies. The route from factory to bedside is more stable, and providers are helping to support US workers and the US economy.

But at the same time, the higher costs are putting pressure on health care; even before the pandemic, most providers were striving to cut budgets. Those pressures will only grow: The pandemic has increased costs at many hospitals (see: the huge increase in the costs of medical gowns), while also reducing revenue due to the enormous number of appointments and elective procedures (which usually generate a substantial amount of a health care systems’ income) that have been canceled and postponed.

So what can we do? I don’t have all the answers, and to be honest, I don’t think anyone does. The first step is to raise awareness of the problem.

On the ground, a potential solution is to return to reusable supplies. Over the past two decades, most hospitals replaced many reusable products with disposables. Johns Hopkins, and I suspect many other systems, will reconsider that choice. And we can do more to conserve supplies, using them carefully and only when necessary.

We also need to diversify our supply chains, connecting with manufacturers in India, Central America, and elsewhere. We can also focus on self-manufacturing; over the past few months, for instance, volunteers at Johns Hopkins have assembled tens of thousands of face shields. Of course, this sort of free labor is not the solution, but local supply handling could help ease the burden somewhat.

Federal and state governments can help by ensuring that domestic product manufacturers aren’t unfairly raising prices, as has apparently occurred in some places. They could also provide financial and logistical support to health care providers so they can better manage higher supply costs.

As this situation continues to evolve, the health care system and its partners will need to develop creative solutions to help ensure that hospitals can continue to afford to keep everyone safe.

Lisa Ishii, a head and neck surgeon, is the senior vice president of operations for Johns Hopkins Health System.

Surgical gowns cost my hospital 40 cents before the pandemic. Now they’re $9.

More than 16.5 million people around the world have been infected by the coronavirus, and the numbers continue to rise steadily. The pandemic has severely disrupted almost every aspect of the global economy, including the global supply chain. Across the world, factories have shut down or slowed production; countries have restricted exports and imports; and transportation has slowed or halted.

While this turmoil has affected many industries, America’s health care system has been hit especially hard. Over the past two decades, US health care has come to rely heavily on international suppliers, especially in China, for thousands of essential products, from surgical gowns to syringes. In fact, as of 2019, the US was the largest importer of medical goods — including of personal protective products — in the world.

Over the past few months as the pandemic raged, most US hospitals and health systems have responded by turning to domestic suppliers. They are more reliable given the difficulties with transportation and trade, which have become worse since the pandemic began.

This trend is likely to continue, as hospitals and health care systems try to ensure that they have a steady supply of essential products.

But this new domestic strategy has a particular disadvantage: In general, it is much more expensive. And this puts hospitals — and, potentially, their patients — in greater financial jeopardy.

Higher domestic prices are likely due to a combination of the increased costs of manufacturing in the US, as well as the booming demand that has outpaced supply. For example, in December, Johns Hopkins Medicine, where I oversee the supply chain, was paying 40 cents for a gown from our supplier in China. We are now paying $9 per gown from a domestic supplier. That’s more than 20 times the former price — all at a time when we need more gowns than ever. This change has the potential to significantly increase health care costs and will only add to the existing strain on health care providers, health insurers, and consumers.

Right now, increased supply costs may not seem like the most important health care issue we face. And it’s not. The immediate task of saving lives obviously takes precedence over all other concerns.

But to save lives, we need personal protective equipment, we need tubing, we need gowns. And we also need to be able to ensure the long-term financial sustainability of our institutions. Without a reliable, affordable supply of a range of products, we can’t properly care for our patients, both those with Covid-19 and those with other health problems.

How the medical supply crisis got so bad
The current supply problems began in January. With the initial coronavirus epidemic in Wuhan and the realization that it would likely spread globally, hospitals around the world began to stock up on supplies, which decreased their availability. Beyond the overall turmoil brought on by the pandemic, China took additional steps to protect itself that further obstructed the supply chain.

In February, to ensure that the country had adequate domestic supply, the Chinese government took over the production and distribution of medical products. China was not the only country to do this, but because it is a leading global supplier of so many health care products — personal protective equipment (PPE) such as N95 masks, medical devices, antibiotics, and pharmaceutical ingredients, to name a few — the decision had major consequences. In 2019 alone, China supplied a quarter of the entire globe’s face masks.

According to the Congressional Research Service, which earlier this year published a report on US imports of medical supplies, China exported in 2019 nearly $21 billion in pharmaceuticals, medical equipment, and health care products to the US. There are no figures yet for 2020, but health care imports from China will almost certainly drop significantly.

For some products, US reliance on China was particularly high. Last year, the US imported $1.9 billion in PPE from China, about 30 percent of our total PPE imports.

China’s response is understandable; it was dealing with a significant disease outbreak. But in the US, this move kicked off shortages of PPE, as well as some medicines, and other important health care products — shortages from which we haven’t yet recovered.

dompeilee. Just curious how do you buy Japanese stocks? What broker are you using? I'm using RHB and there is no direct access to the Japanese market.

https://newsroom.airasia.com/news/2019/10/31/pt-airasia-indonesia-tbk-record-net-profit-after-tax-of-rp-83-billion-in-3q19

Current rally might not last. Might see pullback before rallying again closer to the next quarter result.

If calvin is a journalist he dah lama kena insider trading lol. Bukanlah.

One of the factors I'm most afraid of is Trump's trade war. Too unpredictable for the market.

What's your TP?

Good to buy now at this level after ex?

The infamous Choivo is here too. That's a surprise.

Best to make own decisions. Personally I'm waiting for more indications.

Negatives outweigh the positives for now. Catch with big net when it falls. Durian mau runtuh.

There's no stopping the fall of ADEX for the whole media industry. We are seeing more and more ads on Astro, but those ads carry lesser value than they used to be. More ads, but less money.

That's the reality for newspaper, TV and online media.

Just look at all the news sites too, more and more intrusive ads. But all going deeper in red. Unless the government puts tight leashes on Facebook and Google like Europe, there will be no saving for the local media industry.

Strong lobbying going on behind the scenes.

Hahahaha true too. Hope for the best. Strong feeling that based on track record of Sentosa and strong bilateral ties of both countries, Genting will hit at lease one.

Genting will benefit from Dr. M's constant outreach and official visits there too, especially since GenM did the government a huge favour by buying J Low's floating sin boat.

I'm not confident with Osaka. Yokohama more likely.

There are three chances for Japan casino as there are three locations -- Osaka, Yokohama and Hokkaido.

Most probably will lose the court case.

GenM gained more than Genting ... aduh

In the end not as strong as GenM. Drop back quite abit.

Takes forever to investigate. Takes forever to prove. And takes forever for the court case to finalise. Just search up for the famous cases. See how long those took. No bite.

Yeah insider doing their things. We still don't really know what exactly is going on behind the scenes.

27 cents in one day. Not too bad.

Been sleeping for quite awhile. Finally rallying.

US just shot down an Iranian drone in the Straits of Hormuz. More escalation. More uncertainties and fears. BDI should go up more.

If he resigns also, IF lah, he will pass to his son anyway. Like old Chinese, puppet emperor in the back.

Go to their website, look for investor relations and read.

A few weeks of weak activities then today before lunch suddenly spike up.

Straits of Malacca kena put under terrorism watchlist. Ships going through face high risks so maybe that's why BDI went up like crazy. One of the busiest sea routes in the world.

Tony has unlimited daily supply of korean ginseng. Let's hope for the best.

And Nomura's research is well worth reading as well. AirAsia India seems to be the weakest link in the whole pie right now. Needa sort it asap.

Citi's research paper is a good read compared to local ones. Don't agree on certain things but worth keeping an eye of some things they raised.

Up 18 cents.

Not another quarter lost lol. Not just one most probably two quarters.

You mean manners, not menace.

Anything more about Philippines? Apparently the local partner has increased their stakes to about 40++++ % (can't remember exactly), which is more than AA itself.

Same goes to India where local partners have been increasing their stakes.

Any news on that front?

Financial performance has been terribly poor and yet they keep paying fat bonuses to the AVPs, VPs and big shots.

Attend the AGM tomorrow and whack.

If 7.2 or 7.3 I let go liao.

Remember the warrants expiry?

Just remember. Since 2017, AA has given out 0.12 + 0.12 + 0.12 + 0.4 + 0.12 and soon 0.9 for dividends.

Don't chase high. Buy cheap and hold.

25/6/2019 Q1 (FY20) Results Release

Easily can go up or down about 20-30sen a day.

You will lose that way because the drop is worth more than dividend given.

Been holding AA for years. That one be very careful coz the after ex drop will be much more than the dividend. Not worth it.

I already disposed off GenM. Don't like they stealth move after AGM when they withdrew the judicial review. Should have briefed shareholders more during AGM.

6.9

It's still below 7 as of now.